CD150/SLAMF1 antigen in molecular pathobiology of chronic lymphocytic leukemia / I. Gordiienko [et al.] // Experimental Oncology. - 2017. - Том 39, N 1. - P91-92 MeSH-головна: ЛЕЙКОЗ ЛИМФОЦИТАРНЫЙ ХРОНИЧЕСКИЙ B-КЛЕТОЧНЫЙ -- LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL (терапия) АНТИГЕНЫ -- ANTIGENS Анотація: Recent finding indicate that CD150 cell surface expression can be used as a surrogate prognostic marker of chronic lymphocytic leukemia (CLL) favorable outcome. It was shown that CLL patients with high CD150 expression level on malignant B cells has longer treatment free survival and overall survival compared to patients, which lost CD150 cell surface expression. However, the mechanisms that underlie dependent on CD150 expression biological properties of CLL B cells are not fully understood. Present study was focused on characterization of CD150 topology and isoforms expression, as well as study of CD150 mediated signaling pathways in CLL B cells Дод.точки доступу: Gordiienko, I. Shlapatska, L. Kholodniuk, V. Sklyarenko, L. Sidorenko, S. Вільних прим. немає